A year in the life of Calculus – 2019

3.01.20 It was the year of Brexit (again), another bruising general election, and trauma in the retail fund industry with the demise of Woodford and the gating of property funds. Against this backdrop the VCT and EIS industry continued to … Continued

Oxford BioTherapeutics Initiates U.S. Phase I Clinical Trial

Oxford BioTherapeutics Ltd. (“OBT”), a clinical stage oncology company developing antibody-based immuno-oncology therapies, has announced the initiation of the dose-escalation portion of its U.S. Phase I program for OBT076, a CD205 targeting antibody-drug conjugate (ADC), in patients with advanced solid … Continued

Calculus extends VCT offer to polling day

Calculus Capital has extended its offer to waive initial fees on investments into its Venture Capital Trust (VCT) till December 12th. The move will allow investors to see their adviser before polling stations open. All three parties have published their … Continued

Arecor announces positive results for the first clinical trial

Arecor, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces positive headline results for the Phase I clinical trial of its ultra-rapid acting insulin product candidate, AT247.  In the study, AT247 provided a favourable pharmacokinetic/pharmacodynamic profile compared … Continued

Calculus invests in Wonderhood Studios

Calculus Capital is delighted to announce its investment in Wonderhood Studios, the creative business founded by former Channel 4 CEO David Abraham and senior partners from the TV production and advertising sectors. Wonderhood is introducing a new hybrid model as … Continued

How to use VCTs for retirement

Investors placed £731m into Venture Capital Trusts (VCTs) last year and early indications suggest that they may top that this year. The reason is simple – many of us now use VCTs as a key part of retirement planning alongside … Continued